Remicade®
Understanding Remicade®
Remicade® is a tumor necrosis factor (TNF) inhibitor used to treat various autoimmune diseases by reducing inflammation. As a monoclonal antibody, Remicade® targets TNF-alpha, a protein involved in inflammatory responses, and blocks its activity. This mechanism helps reduce inflammation in joints, the gastrointestinal tract, and the skin, depending on the condition being treated. By doing so, Remicade® slows disease progression and helps prevent long-term damage associated with autoimmune diseases.
How Remicade® Works:
- Blocks TNF-alpha, a key driver of inflammation in autoimmune diseases.
- Reduces symptoms such as joint pain, gut inflammation, and skin irritation in various conditions.
- Helps slow disease progression and prevent long-term tissue damage.
FDA Approval:
- Remicade®: Approved in 1998
For more information, please visit the Remicade® patient website and speak with your healthcare provider to determine if Remicade® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: Ankylosing Spondylitis (AS)Crohn’s Disease (IBD)Cytokine Release Syndrome (CRS)Generalized Pustular Psoriasis (GPP)Giant Cell Arteritis (GCA)Hunter SyndromeInflammatory Bowel Disease (IBD)Juvenile Idiopathic Arthritis (JIA)Kawasaki Disease (KD)Non-radiographic Axial Spondyloarthritis (nr-axSpA)PsoriasisPsoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Spondyloarthropathies (SpA)Still’s Disease (AOSD)Ulcerative Colitis (UC) |
MANUFACTURER: Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) |
CLASS: Tumor Necrosis Factor (TNF) Inhibitor
Monoclonal Antibody (Biologic Therapy) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Three times in the first six weeks, then every eight weeks |
Length of infusion: About two hours |
FOR MORE INFORMATION: |
Related drugs
